Skip to content
Screener

Travere Therapeutics, Inc. TVTX Business Segments — Other research and development

Similar metrics at other companies

Inhibrx Biosciences, Inc. logo
INBXReportable Segment — Other research and development
$2.91M-7.8%
Alto Neuroscience logo
ANROReportable segment — Other research and development
$1.2M+6.1%
Incyte logo
INCYReportable Segment — Other research and development
$0-100%
Inhibrx Biosciences, Inc. logo
INBXReportable Segment — Other Research and Development Expense
$2.91M-7.8%
Silicon Laboratories logo
SLABReportable Segment — Other research and development expenses
$56.28M+1.9%
Archer Aviation logo
ACHRReportable Segment — Other research and development expense
$133.3M+51.1%

Other financials

Income statement

See full
Revenue$127.2M+55.6%
Gross profit$125.2M+62.5%
Operating income-$36.9M+13.5%
Net income-$37.1M+10.0%
EPS (diluted)-$0.40+14.9%

Balance sheet

See full
Cash & equivalents$78.4M+26.6%
Total debt$15.6M-82.6%
Total equity$98.7M+201%
Total assets$555.2M+1.2%

Cash flow

See full
Operating cash flow-$40.4M+4.3%
CapEx$140.0K—
Free cash flow-$42.5M+28.1%

Valuation

See full
Market cap$5.89B+284%
Enterprise value$5.82B+277%
P/S11×+6.4×

Profitability

See full
Gross margin98.6%+2.6pp
Operating margin-10.6%-5.0pp
Net margin-20.3%-9.5pp
FCF margin-133.9%-34.4pp

Returns & leverage

See full
Return on equity-706%-1,302pp
Debt / equity0.2×-2.6×
Current ratio3.1×+1.1×

Where this comes from

Reported directly by Travere Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.

The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:45 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001438533-26-000042
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Research and development:
External research and development27,72822,355
Internal personnel costs24,52520,102
Other research and development4,8414,432
Total research and development57,09446,889
Selling, general and administrative80,25460,413
Royalty expense24,81612,425
Total other income, net1931,487

Item 1. Financial Statements

FAQ

What is Travere Therapeutics, Inc.'s business segments — other research and development?
Travere Therapeutics, Inc. (TVTX) reported business segments — other research and development of $4.84M in Q1 2026.
How has Travere Therapeutics, Inc.'s business segments — other research and development changed year-over-year?
Travere Therapeutics, Inc.'s business segments — other research and development increased by 9.2% year-over-year, from $4.43M to $4.84M.
What is the long-term trend for Travere Therapeutics, Inc.'s business segments — other research and development?
Over 3 years (2022 to 2025), Travere Therapeutics, Inc.'s business segments — other research and development has grown at a -4.9% compound annual growth rate (CAGR), from $21.97M to $18.88M.
What does business segments — other research and development mean?
This metric includes miscellaneous research and development costs not categorized as direct external trial expenses or internal personnel costs, such as laboratory supplies or overhead. It provides visibility into the ancillary operational costs required to maintain a functional R&D environment.

Ask your AI about Travere Therapeutics, Inc.'s business segments — other research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude